- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT03666624
Socially Isolated Older Adults Living With Dementia
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
We will address the following aims:
Aim 1. Develop a personalized care network-RDAD intervention suitable for SGM older adults living with dementia without caregivers.
Aim 2. Implement a preliminary randomized controlled trial (RCT) of 30 participants with 2 arms (routine medical care vs. the personalized care network-RDAD approach) to assess the acceptability, feasibility, and initial efficacy of the intervention.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Washington
-
Seattle, Washington, États-Unis, 98195
- UWashington
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age at enrollment is 50 years of age or older
- Self-identify as LGBT (or sexual or gender non-binary or same sex sexual behavior)
- Have early stage dementia, including Alzheimer's disease or needs help with complex daily activities
- Living in the community, not in a care facility.
Exclusion Criteria:
- Known terminal illness (with death anticipated within the next 12 months)
- Hospitalization for a psychiatric disorder in the 12 months prior to baseline
- Have more than early stage dementia
- Any physical limitations/chronic conditions preventing participation in an exercise program.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Personalized care network
9 60-minute virtual sessions for 6 weeks plus personalized exercise coaching once a week for 6 weeks
|
The Personalized care network intervention includes exercise training for participant with dementia and behavioral management training for addressing challenges.
|
|
Aucune intervention: Routine medical care
No intervention
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Physical Activity
Délai: Baseline (pre-treatment) and 7 weeks (post-treatment)
|
Minutes spent on exercising per week in the past month were calculated from the following two questions: (1) How much time did you spend on exercises (hours per day) on a typical day during the last month; (2) How many days did you spend on exercises during the last month.
|
Baseline (pre-treatment) and 7 weeks (post-treatment)
|
|
Change in Physical Functioning
Délai: Baseline (pre-treatment) and 7 weeks (post-treatment)
|
Physical Functioning subscale of the Medical Outcomes Study 36-Item Short Form (SF-36) consists of 10 items and measures how much participants' health status limits their activities including walking, climbing, lifting, and bathing or dressing oneself, based on self-reports.
Each item is measured a 3-point scale (1 = Yes, limited a lot; 2 = Yes, limited a little; 3 = No, not limited at all), then recoded into 0, 50, and 100, respectively.
The recoded scores are averaged to generate a summary score with its possible range from 0 to 100.
Higher scores indicate better physical functioning.
|
Baseline (pre-treatment) and 7 weeks (post-treatment)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Quality of Life
Délai: Baseline (pre-treatment) and 7 weeks (post-treatment)
|
Quality of Life in Alzheimer's Disease (QOL-AD) is a 13-item scale that measures participant's self-reported feelings about different aspects of life including energy, mood, living situation, memory, family, friends, ability, and money.
Each item has a 4-point response scale (1 = poor; 2 = fair; 3 = good; 4 = excellent).
The summary score is a sum of the 13 items with its possible range from 13 to 52.
Higher scores indicate higher quality of life.
|
Baseline (pre-treatment) and 7 weeks (post-treatment)
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Directeur d'études: Hyun-Jun Kim, PhD, University of Washington
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- STUDY00005149
- 5P30AG034592-05 (Subvention/contrat des NIH des États-Unis)
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .